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Wssociation of Gene Polymorphisms
ith Coronary Artery Disease in
ow- or High-Risk Subjects
efined by Conventional Risk Factors
e read with interest the careful study by Hirashiki et al. (1), who,
pon examining 37 single nucleotide polymorphisms (SNPs) in 31
andidate genes, reported a significant association of coronary
rtery disease (CAD) with SNPs in the apolipoprotein E,
onnexin-37, stromelysin-1, and endothelial nitric oxide synthase
eNOS) genes. A polymorphism in the promoter (T786C) of the
atter gene was recently shown to bear functional consequences (2)
ecause the C allele creates a binding site for a replication protein
-1 that acts as a repressor of gene transcription (3). Accordingly,
ssential hypertensive patients carrying this allele exhibited a
lunted forearm vasodilation in response to acetylcholine (4). This
llele was shown to be significantly associated with coronary
asospasm and myocardial infarction (MI) in Japanese patients
2,5) and with multivessel CAD in consecutive Caucasian patients
ndergoing coronary angiography because of suspected CAD (6).
hus, the results of Hirashiki et al. (1) in the Japanese patient
opulation appear to be fully confirmatory of earlier reports (5),
ncluding our study of Caucasians (6), that were overlooked.
Based on the presence or absence of hypertension, hypercho-
esterolemia, and diabetes mellitus, subjects in the Hirashiki et al.
tudy (1) were divided into a high- and a low-risk group,
espectively, yet about 74% of their CAD patients had myocardial
nfarction (MI) and therefore cannot be considered at low risk.
ndeed, according to the Third Report of the National Cholesterol
ducation Program Expert Panel (Adult Treatment Panel III) (7),
hese individuals would represent high-risk patients (e.g., subjects
ith a 20% risk of cardiovascular events in the next 10 years).
oreover, as the investigators correctly pointed out, their popu-
ation comprises MI survivors. Thus, it remains unclear whether
he SNPs that showed a significant association with CAD in a
opulation that mainly comprised high-risk MI survivors repre-
ented markers of survival or of predisposition to CAD (e.g.,
rotective or nefarious genetic variants). In our consecutive pa-
ients, a minority (45.6%) had a history of MI (6). Accordingly,
lthough the mortality for MI might be higher in Western
ountries than in Japan, the majority of our patient population did
ot comprise MI survivors.
The significant association of the 786C allele with CAD was
onfirmed by Hirashiki et al. also in their high-risk men; however,
he researchers did not comment on this important finding. Of
nterest, we tested the hypothesis that the genetic predisposition to
enerate less nitric oxide (NO) was more detrimental under
onditions with blunted NO availability, such as age older than 60
ears, hypercholesterolemia, cigarette smoking, and low high
ensity lipoprotein (HDL) cholesterol. With such analysis we
ound not only a significant association of multivessel CAD with
he 786C allele but also, more importantly, a marked increase in
he relative risk of multivessel CAD from 1.7 (95% confidence
nterval: 1.11 to 2.55, p  0.014) in the overall population to 3.61
1.63 to 8.0, p  0.002) when at least four such conditions
oexisted. Thus, one of the SNPs that was found to be associated
ith CAD by Hirashiki et al. (1) does not seem to increase the risk of CAD independently of other risk factors. Instead, it appears to
eeply interact with environmental factors that blunt NO availability.
It must be kept in mind that association studies are peculiarly prone
o false positive results, particularly when controls are not randomly
elected, as in the study by Hirashiki et al. (1). Based on dividing the
atients into low- and high-risk groups, the investigators pinpointed
NPs that were significantly associated with CAD in low- and
igh-risk groups of men and women. As the investigators correctly
cknowledged, the large number of comparisons that were made
pened up the possibility of chance findings; furthermore, no infor-
ation on power of the subgroup analyses was furnished. Nonethe-
ess, the independent replication by Hirashiki et al. in a genetically
nrelated population of our report of an association of the 786C allele
ith multivessel CAD lends strong support to our conclusion that this
NP is an important genetic factor predisposing to the development
f multivessel CAD.
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e thank Drs. Rossi and Maiolino for their comments regardingur paper (1). Beyond 2020, it is likely that genetic identification
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July 7, 2004:209–13f the risk factors will lead to gene-informed personalized preven-
ion (2). It is thus important to identify genes that confer
usceptibility to coronary artery disease (CAD). Furthermore,
tratification of subjects based on conventional risk factors for
AD and prospective cohort studies are also important to accom-
lish personalized medicine. In our study (1), low-risk individuals
ere defined as those who did not have any of the three major risk
actors (hypertension, diabetes mellitus, and hypercholesterol-
mia). Given that the study is a cross-sectional association study,
he classification of subjects as low-risk or high-risk was not based
n the prevalence of myocardial infarction (MI) after follow-up of
0 years. Although a survivor bias could not be excluded com-
letely, it was likely to be small in our study because of a relatively
ow prevalence of fatal MI (approximately 20%) in Japan. The
ariant alleles of four single nucleotide polymorphisms (SNPs)
ignificantly associated with CAD are thus markers of predispo-
ition to CAD.
Although the 786T3C SNP of the endothelial nitric oxide
eNOS) gene was related to CAD in the total population and in
igh-risk men, the p values were 0.0484 (additive model) and
.0369 (dominant model), respectively (1). In an initial screening
f the 112 polymorphisms for association with MI in 909 subjects
n our previous study (3), the 786T3C SNP of eNOS gene was
elated to MI in men and women. In a large-scale association
tudy, however, this SNP was not significantly associated with MI
n men or women (3). The characteristics of ideal association study
nclude a large sample size, small p values, an association that
akes biological sense, and alleles that affect the gene product in
physiologically meaningful way (4). Two studies with a p value of
0.01 or a single study with a p value of 0.001 other than the
rst positive study is strongly predictive of future replication (5).
iven that we adopted a criterion of a p value of 0.005 as
tatistical significance for association (1), the relation of the
786T3C SNP of eNOS gene with CAD was considered not to
e significant. Although this SNP was shown to be associated with
oronary artery spasm (6), the relation of this SNP with CAD
emains to be elucidated.
In a stepwise forward selection procedure, four SNPs signifi-
antly associated with CAD were all statistically independent of
ge, smoking, or hyperuricemia as well as hypertension, diabetes
ellitus, and hypercholesterolemia. As Drs. Rossi and Maiolino
oint out, the presence of hypertension, diabetes mellitus, and
ypercholesterolemia may blunt nitric oxide availability. However,
he 1019C3T SNP of the connexin-37 gene in high-risk men and
he 3932C3T SNP of the apolipoprotein E gene in high-risk
omen were statistically independent of these risk factors.
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herapeutic Transcutaneous
ltrasound: Long Overdue Therapy
he recent report by Miyamoto et al. (1) presents the results of an
xperimental study evaluating the coronary vessel dilatory effect of
ranscutaneous low-frequency ultrasound. The investigators used a
uite sophisticated animal model and demonstrated by various
eans that transcutaneous ultrasound induces vasodilation in
anine coronary arteries. The magnitude of the effect was similar to
hat found with intracoronary nitrates. The researchers very
orrectly concluded that this phenomenon may be used as a
herapeutic tool to reduce myocardial ischemia in patients with
cute coronary syndromes.
Interestingly, in 1980 we first performed experimental and later
linical studies using approximately similar doses of transcutaneous
ltrasound. The ultrasound frequency in our study was 790 to 910
Hz, with the ultrasound of 0.2 to 0.45 W/cm2. The first case of
ranscutaneous ultrasound therapy in a patient was performed in
arly 1981 and later published in a USSR patent (2).
We completely agree with the editorial comments of Drs.
cPherson and Holland (3) who postulated that this effect of
ltrasound is strictly mechanical (acoustic radiation, streaming,
nd cavitation). Recently, we demonstrated that similar effects can
e achieved with other forms of electromagnetic radiation (4,5).
In conclusion, we want to congratulate the investigators on a
ery interesting study, and we believe that further preclinical and
linical data may prove the safety and efficacy of this long overdue
orm of therapy, namely transcutaneous therapeutic ultrasound for
reatment of ischemia.
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